Monday, January 31, 2011

News from the Ken Olsen Science Center--Student Contributions to the Medical Field

Chemistry student Carl Quinion's summer research work is receiving some international attention. Quinion, now in his senior year, has spent the last two summers doing research under the direction of Dr. Robert Baiocchi at Ohio State University's Comprehensive Cancer Center. The research focused on a new possible treatment option for patients with mantle cell lymphoma (MCL), an extremely aggressive cancer. The treatment consists of a combination of two highly selective drugs and is shown to be highly effective in both in vivo (in a living organism) and in vitro studies. The importance of this research is highlighted by the fact that MCL is generally considered incurable. With the support of this data, phase-1 clinical trials have begun.

Quinion's many hours of dedication have resulted in the coauthorship of a paper published in a national medical journal by the American Society of Hematology. The paper's title may not be the easiest to say--"Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma"--but the results may provide hope for those suffering from one type of highly aggressive lymphoma.

"I am grateful to have had the opportunity to contribute to research that could directly help individuals suffering from lymphoma," says Quinion. "It was fascinating to observe and participate in the process of medical research. My experiences in the lab gave me a new appreciation for medical discovery. I would completely recommend similar research opportunities to any student considering a career in the sciences."

When not in the labs of the Ken Olsen Science Center, Quinion is taking classes and preparing for a year of research at Ohio State at the invitation of Dr. Baiocchi before going to medical school.

Blood, the most cited peer-reviewed publication in the field of hematology, has an outreach of over 10 million readers.

No comments: